Secukinumab
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Secukinumab
- Secukinumab: From Inflammatory Conditions (Original Indication Not Recorded) to Primary Release Disorder of Platelets
Secukinumab: From Inflammatory Conditions (Original Indication Not Recorded) to Primary Release Disorder of Platelets
One-Sentence Summary
Secukinumab is an anti-IL-17A monoclonal antibody that is marketed in Singapore as Cosentyx, but the approved-indication text was not captured in the data compiled for this report. The TxGNN model predicts it may be effective for primary release disorder of platelets, but no clinical trials and no relevant publications support this prediction. It rests on a graph-based score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in the data compiled for this report (the licence records contain no indication text) |
| Predicted New Indication | Primary release disorder of platelets |
| TxGNN Prediction Score | 98.16% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 4 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the compiled data. From general knowledge, secukinumab neutralises interleukin-17A (IL-17A), a cytokine involved in inflammatory and autoimmune skin and joint disease. The compiled data did not record its original indications.
The predicted disease is a primary release (secretion) defect of platelets. This is an intrinsic platelet function disorder, and it is not known to be driven by IL-17A. The review of this prediction found no plausible mechanistic link. The high TxGNN score (rank 16,221) is a graph-derived signal only and has no supporting trials or literature.
The same applies to the other top-ranked predictions, such as pseudo-von Willebrand disease, Glanzmann thrombasthenia and fetal and neonatal alloimmune thrombocytopenia. These are platelet or bleeding disorders with causes unrelated to IL-17A. Some lower-ranked predictions have a weak rationale. For example, IL-17A contributes to bone resorption in inflammatory settings, which gives drug-induced osteoporosis a weak biological basis. These were also not supported by any studies.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
For context, publications were retrieved for a lower-ranked prediction (luminal A/B breast tumour), but they cover secukinumab in other diseases and do not address that indication. They include the phase 3 SUNSHINE/SUNRISE trials in hidradenitis suppurativa (PMID 36746171), psoriasis and axial spondyloarthritis. They appear to be keyword-matching artifacts. Hidradenitis suppurativa could be assessed separately as a candidate indication.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN16359P | COSENTYX Solution for Injection in Pre-filled UnoReady Pen 300mg/2ml | Injection, solution | Not recorded |
| SIN14751P | COSENTYX Solution for Injection in Prefilled Syringe 150mg/ml | Injection, solution | Not recorded |
| SIN14750P | COSENTYX Solution for Injection in Prefilled SensoReady Pen 150mg/ml | Injection, solution | Not recorded |
| SIN16315P | COSENTYX Solution for Injection in Prefilled Syringe 75mg/0.5ml | Injection, solution | Not recorded |
Safety Considerations
- Drug Interactions: 100 interactions were identified. The most notable is adalimumab (Major), so combining secukinumab with other immunosuppressive biologics needs particular caution. Moderate-level interactions include warfarin, apixaban, rivaroxaban, dicoumarol, simvastatin, tacrolimus, theophylline and aminophylline, roflumilast, fentanyl, hydrocodone, lidocaine, nifedipine and tetanus toxoid vaccine. Minor interactions include several zinc salts.
- Infection risk: A consensus document on biologic safety, retrieved with the literature, discusses infection risk with IL-17 and other cytokine-targeted agents.
- Gastrointestinal effects: A review reports paradoxical gastrointestinal effects of IL-17 blockers, including worsening of inflammatory bowel disease.
For warnings and contraindications, please refer to the package insert.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a graph-based score. There are no trials or literature, and there is no plausible link between IL-17A blockade and a platelet release defect. The evidence level is L5.
To proceed, the following is needed:
- Mechanism of action data and a documented mechanistic rationale linking IL-17A to platelet release disorders
- Package insert warnings and contraindications, and approved-indication text for the Singapore licences
- Any preclinical or clinical evidence in platelet function disorders
- Consideration of better-supported candidates, such as hidradenitis suppurativa, which has phase 3 RCT data and should be evaluated separately
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.